NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

LL herself has talked on the video from last year as she notes RA want patient level data for EC comps.

All detailed patient data has, of course, been provided to the MHRA by NWBO. So what is your problem here exactly?
Over and over you keep repeating the same nonsense. The non-existence in and exclusion criteria problems, that you and some others have made up, have been tackled extensively when comparing DCVAXL patient data to EC comps.

And goes on to say how she hopes -L can be made available by some kind of RTT while studies are run to prove the OS benefit.

LL never said. She could not have said that because there already is an extensive RTT in the UK its called compassioned use.